Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.00
Bid: 40.00
Ask: 40.90
Change: 0.00 (0.00%)
Spread: 0.90 (2.25%)
Open: 40.00
High: 40.00
Low: 40.00
Prev. Close: 40.00
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Market Authorisation Update

3 May 2022 07:00

RNS Number : 9826J
Benchmark Holdings PLC
03 May 2022
 

3 May 2022

 

Benchmark Holdings plc

("Benchmark", the "Company" or the "Group")

 

Ectosan® Vet

Variation to Marketing Authorisation enabling a second use of treatment water

An important milestone towards optimal efficiency of Benchmark's transformational sea lice solution

 

Benchmark (LSE: BMK), the aquaculture biotechnology company, is pleased to announce that it has been granted a variation to its Marketing Authorisation ("MA") for Ectosan® Vet from the Norwegian Medicines Agency ("NoMA").

 

This variation to the MA enables the re-use of the treatment water for a second batch of fish, subject to water quality being maintained to the satisfaction of the prescribing veterinarian, therefore increasing the efficiency of treatments. This means a producer will be able to treat a salmon farm more efficiently with a solution that delivers more than 99% efficacy, promotes animal welfare, reduces mortality and protects the environment - driving sustainability in the industry.

 

This MA variation represents a further important step towards our goal of optimising the efficiency of our sea lice solution, and further trials are ongoing to support multiple re-use of treatment water.

 

 Trond Williksen, CEO, commented:

 

"We are very pleased to have been granted a variation to the Marketing Authorisation from the Norwegian Medicines Agency. This represents an important milestone for the Company and for the industry. Ectosan® Vet and CleanTreat® is a much needed solution for the industry which continues to show excellent results with efficacy above 99% as well as good operational efficiency. It is the first medicinal solution brought to the Norwegian market in over ten years which addresses one of the biggest challenges in salmon production, while improving animal welfare, reducing mortality and protecting the environment."

 

Enquiries:

 

Benchmark Holdings plc

Tel: 020 3696 0630

Trond Williksen, CEO

Septima Maguire, CFO

Ivonne Cantu, Investor Relations

 

 

 

Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black / Freddie Barnfield / Duncan Monteith

 

 

 

MHP

 

Katie Hunt/Charlie Protheroe/Fergal Bettridge-Boyd

Tel: 020 3128 8990

benchmark@mhpc.com

 

 

 

 

 

About Benchmark 

Benchmark is a market leading aquaculture biotechnology company. Benchmark's mission is to drive sustainability in aquaculture by delivering products and solutions in genetics, advanced nutrition and health which improve yield, growth and animal health and welfare.

Through a global footprint in 26 countries and a broad portfolio of products and solutions, Benchmark addresses the major aquaculture species - salmon, shrimp, sea bass and bream, and tilapia, in all the aquaculture regions around the world. Find out more at www.benchmarkplc.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBLLLBLELZBBL
Date   Source Headline
9th Jul 20197:00 amRNSDirectorate Change
2nd Jul 20193:49 pmRNSHolding(s) in Company
2nd Jul 20197:00 amRNSHolding(s) in Company
28th Jun 20194:41 pmRNSSecond Price Monitoring Extn
28th Jun 20194:35 pmRNSPrice Monitoring Extension
28th Jun 20192:05 pmRNSSecond Price Monitoring Extn
28th Jun 20192:00 pmRNSPrice Monitoring Extension
28th Jun 20197:00 amRNSTotal Voting Rights
25th Jun 20197:00 amRNSInterim Results
13th Jun 20198:00 amRNSPlacement of a new senior secured bond issue
10th Jun 20197:00 amRNSUpdate on Joint Venture with AquaChile
3rd Jun 20197:00 amRNSTrading Update and Investor Meetings
31st May 20197:00 amRNSTotal Voting Rights
29th May 20197:00 amRNSUpdate on Joint Venture with AquaChile
30th Apr 20197:00 amRNSTotal Voting Rights
29th Mar 20192:25 pmRNSReplacement: Total Voting Rights
29th Mar 20197:00 amRNSTotal Voting Rights
21st Mar 20197:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
14th Mar 201912:21 pmRNSResult of AGM
28th Feb 20197:00 amRNSTotal Voting Rights
20th Feb 20197:00 amRNSAppointment of Non-Executive Director
29th Jan 20193:07 pmRNSPosting of Annual Report & Notice of AGM
28th Jan 20198:00 amRNSDIRECTOR SHARE OPTIONS
24th Jan 20197:00 amRNSFull Year Results
14th Jan 20197:00 amRNSNotice of Results
31st Dec 20188:00 amRNSTotal Voting Rights
12th Dec 20183:08 pmRNSDirector/PDMR Shareholding
12th Dec 201811:01 amRNSHolding(s) in Company
10th Dec 20185:05 pmRNSHolding(s) in Company
7th Dec 20183:35 pmRNSHolding(s) in Company
30th Nov 20187:00 amRNSTotal Voting Rights
30th Nov 20187:00 amRNSTotal Voting Rights
27th Nov 20187:00 amRNSSuccessful defence of patent infringement in Asia
7th Nov 20187:00 amRNSTrading Statement
31st Oct 20187:00 amRNSTotal Voting Rights
23rd Oct 20184:55 pmRNSHolding(s) in Company
22nd Oct 20185:52 pmRNSHolding(s) in Company
10th Oct 20182:53 pmRNSDIRECTOR DEALINGS
3rd Oct 20187:00 amRNSAcquisition and Issue of Equity
2nd Oct 20187:00 amRNSAppointment of Chief Scientific Officer
28th Sep 20187:00 amRNSTotal Voting Rights
21st Sep 20187:00 amRNSBlock listing Interim Review
12th Sep 20187:00 amRNSBlock Admission Application
10th Sep 20187:00 amRNSCommencement of salmon egg production in Salten
30th Aug 20187:00 amRNSTotal Voting Rights
30th Jul 20187:00 amRNSTotal Voting Rights
2nd Jul 20187:00 amRNSAppointment of Executive Director
29th Jun 20187:00 amRNSTotal Voting Rights
27th Jun 20184:36 pmRNSHolding(s) in Company
25th Jun 20184:01 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.